Form 4: Arbutus Biopharma Interim CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Michael J. McElhaugh, Interim President & CEO of Arbutus Biopharma, sold 23,790 common shares on February 4, 2025, to cover tax obligations related to vesting restricted stock units.
Summary
- On February 4, 2025, Michael J. McElhaugh, the Interim President & CEO of Arbutus Biopharma Corp, sold 23,790 common shares of the company.
- The sale was executed at a price of $3.283 per share.
- This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on March 3, 2023.
- The purpose of the sale was to satisfy tax obligations related to the vesting of previous grants of restricted stock units.
- Following the transaction, McElhaugh still beneficially owns 1,481,003 common shares of Arbutus Biopharma.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing relates to a routine stock sale for tax purposes under a pre-existing plan.
Industry Context
This is a routine Form 4 filing related to insider trading activity. It is common for executives to sell shares to cover tax obligations, especially after vesting of restricted stock units.
Stakeholder Impact
- The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, but it is likely to be minimal given the context of tax obligations and the pre-arranged trading plan.
Key Dates
| Date | Description |
|---|---|
| 2019-08-15 | Date of Power of Attorney execution. |
| 2023-03-03 | Date of adoption of the 10b5-1 trading plan. |
| 2025-02-04 | Date of the stock sale transaction. |
| 2025-02-05 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.